SynAct nears US patent for resomelagon tablet
SynAct Pharma has received a Notice of Allowance from the US Patent and Trademark Office (USPTO) for a patent covering the tablet formulation of resomelagon, its lead drug candidate. Once granted, the patent will protect the clinical dosage form until at least June 2042.
The Lund-based company expects the patent to be granted within a few weeks, once it has paid the issue fee. The application covers the immediate-release solid oral formulation of resomelagon (AP1189 acetate) currently in clinical testing. The allowance follows a favorable decision from the USPTO’s Patent Trial and Appeal Board (PTAB), which SynAct announced earlier. The protection runs to June 2042 before any patent term adjustment, which has not yet been determined.
“The Notice of Allowance is an important step in SynAct’s strategy to strengthen the intellectual property protection around resomelagon. It reflects our diligent efforts to execute on the overall strategy to protect key assets in our development program,” says Thomas Boesen, COO of SynAct Pharma.
SynAct already holds two US patents covering the crystal form of resomelagon. One of them, extended by a patent term adjustment, runs until July 2, 2044.
Resomelagon is an oral, once-daily selective melanocortin agonist being developed on two tracks. In rheumatoid arthritis, it is being tested in combination with first-line methotrexate therapy. In viral infections, SynAct is exploring whether it can resolve excessive inflammation in patients with severe viral disease, including respiratory infections and dengue.
Published: November 16, 2026
